Table 1.

Comparison of patient demographics, tumour size and baseline biochemical evaluation of thyroid function in adenomas according to type

						P-value
	All adenomas (n = 149)	ACTH adenomas (n = 34)	Non-ACTH adenomas (n = 115)	PRLomas (n = 72)	NFAs (n = 43)	ACTH vs Non-ACTH	PRL vs NFA
No. female/male (%)	120/26 (81/19)	33/1 (97/3)	87/25 (76/24)	59/13 (82/18)	28/12 (65/35)	0·009	0·16
Mean age (years)	35·6 ± 1·2	38·4 ± 2·2	34·8 ± 1·3	33·7 ± 1·4	36·5 ± 2·6	0·18	0·30
Maximal tumour diameter (mm)	5·26 ± 0·18 (n = 123)	5·82 ± 0·39 (n = 28)	5·11 ± 0·20 (n = 95)	5·18 ± 0·24 (n = 62)	4·98 ± 0·33 (n = 33)	0·09	0·63
Normalized free T4	1·45 ± 0·02 (n = 149)	1·29 ± 0·06 (n = 34)	1·50 ± 0·23 (n = 115)	1·52 ± 0·03 (n = 72)	1·47 ± 0·04 (n = 43)	0·0001	0·30
Normalized TSH	0·46 ± 0·02 (n = 145)	0·42 ± 0·06 (n = 34)	0·47 ± 0·03 (n = 111)	0·46 ± 0·03 (n = 71)	0·50 ± 0·04 (n = 40)	0·36	0·47

PRLomas, prolactinomas; NFA, nonfunctioning adenomas. Bold font indicates statistically significant P-values.